- Research article
- Open Access
Isoflavones prevent bone loss following ovariectomy in young adult rats
© Tsuang et al; licensee BioMed Central Ltd. 2008
- Received: 18 February 2007
- Accepted: 02 March 2008
- Published: 02 March 2008
Soy protein, a rich source of phytoestrogens, exhibit estrogen-type bioactivity. The purpose of this study was to determine if ingestion of isoflavones before ovariectomy can prevent bone loss following ovariectomy. Twenty-four nulliparous Wistar rats were randomly divided into four groups. In the normal diet groups, a sham operation was performed on Group A, while ovariectomy was performed on Group B. For Groups C and D, all rats were fed with an isoflavone-rich (25 mg/day) diet for one month, then bilateral ovariectomy were performed. In the rats in Group C, a normal diet was begun following the ovariectomy. The rats in Groups D continued to receive the isoflavone-rich diet for two additional months postoperatively. All rats were sacrificed 60 days after surgery. The weight of bone ash of the long bones and whole lumbar spine were determined. A histological study of cancellous bone was done and biochemical indices of skeletal metabolism were performed and analyzed. The markers of bone metabolism exhibited no significant changes. When compared with the sham-operated rats fed a normal diet, the bone mass of ovariectomized rats decreased significantly; pre-ovariectomy ingestion of an isoflavone-rich diet did not prevent bone loss. The bone mass of rats treated with an isoflavone-rich diet for three months was higher than controls two months after ovariectomy.
Dietary isoflavones did not prevent the development of post-ovariectomy bone loss, but long-term ingestion of an isoflavone-rich diet increased the bone mineral contents after ovariectomy in young rats.
- Bone Mineral Density
- Bone Loss
- Bone Mass
- Cancellous Bone
- Normal Diet
Osteoporosis is a complex disease characterized by a reduction in bone mass with associated microarchitectural deterioration and a correspondingly high risk of fractures. It is a serious and costly public health problem in the elderly population . Osteoporotic fractures are an important cause of disability. Osteoporosis and the consequences of compromised bone strength, particularly vertebral and hip fractures, is a significant cause of increased morbidity and even mortality. Hip fractures are associated with a 20% mortality in the year following the fracture . As driven by the aging of the baby boomers and by the increasing longevity, the size of the population aged 50 years or older will increase markedly during the next several decades. Consequently, the cost of managing fractures is substantial and will continue to rise . Thus, the direct, as well as indirect, costs of fractures are expected to increase correspondingly worldwide .
Recent epidemiological studies have suggested that the incidence of osteoporosis varies among populations, as the result of the complex interactions of a variety of genetic, geographic, and ethnic factors [5–7]. Although family and twin studies have suggested that there is a strong genetic component which predisposes to osteoporosis, environmental factors like nutrition, mechanical load, and lifestyle are also important . The relative impact of environmental and genetic factors on the predisposition to osteoporosis is still a matter of debate.
Investigation of the role of dietary habits on the development and prevention of postmenopausal osteoporosis has focused primarily on calcium intake and vitamin D repletion. These two factors, albeit important, only account for the development of osteoporosis in part. Indeed, the incidence of osteoporosis in homogeneous populations correlates inversely with calcium intake , and it appears that the highest total incidence of fractures is experienced by populations with the highest calcium consumption . Since differences in nutrition between populations can be striking and are not limited to calcium intake, it is possible that other macro- and micro-nutrients may contribute to the different incidence of fractures between populations .
Recently, the beneficial effects of various classes of phytoestrogens present in nature were reported . Phytoestrogens are abundant in plants and have received increasing attention as dietary components that can affect several aspects of human health . Phytoestrogens are non-steroidal plant molecules whose structure differs from gonadal hormones, yet have estrogen-type bioactivity [12, 14]. The notion that phytoestrogens may affect osteoporosis favorably has emerged recently  and is supported by the observations that phytoestrogens are beneficial for manifestations of the postmenopausal state such as hyperlipidemia  and hot flushes . Moreover, the synthetic phytoestrogen, ipriflavone, exerts positive effects on the bone mass of postmenopausal women  and experimental animals . This beneficial effect has also been reported from human feeding trials [20, 21].
Soy protein and flaxseed are the most common sources of phytoestrogens in the Western diet. This study was designed to elucidate whether long term systemic administration of an isoflavone-rich diet is capable of preventing the rapid bone loss occurring after surgical castration in young female rats and, if it is, to gain insight into the mechanisms of this effect.
Experimental Design (n = 6)
Isoflavone-rich diet 1st month
Isoflavone-rich diet 2nd & 3rd months
Under general anesthesia with ketamine, ovariectomy was performed by ligation and excision of the ovaries along the upper horns. In the sham operation, the ovaries were exposed as above and gently manipulated, but not excised. In an unpublished pilot study, we demonstrated that bone loss occurs three weeks after ovariectomy. In the early morning after a 12 hour fast, the isoflavones were administered via a funnel-shaped feeding tube through the mouth once a day. During the daytime, the animals were fed Purina Laboratory Chow ad libitum and housed in a temperature-, humidity-, and light-controlled environment. Surgical procedures and experimental protocols were approved and under the supervision of the Animal Research Committee of the National Taiwan University. The rats were sacrificed 60 days after surgery by methofane injection and exsanguination (i.e., on day 90 of the study). For all rats, whole blood samples were obtained with plastic syringes via intracardiac puncture both before surgery and immediate after death. The blood samples were put on ice, centrifuged to separate the serum, divided into aliquots of 500 μl, and deep-frozen at -80°C until further analysis.
After sacrificing the rats, the long bones of the hindlimb, including the femur and tibia, and the thoracolumbar spine, were harvested promptly. The long bones of the right hindlimb and the whole lumbar vertebrae, were trimmed of soft tissue and burned; the weight of bone ash of each bone was then measured for further analysis. A histological study of cancellous bone was done on the proximal femur, the proximal tibia of the left limb, and the last thoracic vertebrae. After necropsy, the last thoracic vertebrae and long bones were dissected out and fixed with 4% formaldehyde in phosphate-buffered solution for 18 hours, followed by decalcification, and then dehydrated in alcohol, cleared in xylene, and embedded in paraffin. Sections, 5 to 7 μm in thickness, were cut and stained with hematoxylin and eosin. Representative sections were photographed using light microscopy. The thickness and interconnections between trabeculae were recorded. The histological observation of bone tissue was performed by a MICD image analyzing system (MICD Software Series, Image Research Inc., Ontario, Canada). The mean percent of porosity of bone tissue was measured by dividing the observed area, without bone tissue, by the whole area.
Biochemical indices of skeletal metabolism, such as alkaline phosphatase (ALP; procedure no. ALP-10, Sigma Co., St. Louis, MO, USA), aspartate aminotransferase, and alanine aminotransferase (AST/GOT and ALT/GPT; procedure no. 505-OP, Sigma Co.), amylase (AMY; procedure no. Amylase-10, Sigma Co.), creatinine (CRE; procedure no. 555-A, Sigma Co.), calcium (CA; procedure no. 587-100P, Sigma Co.), and inorganic phosphorus (IP; procedure no. 363-3-100P, Sigma Co.) content in the serum were measured with commercially available assay kits. Parathyroid hormone (PTH) content in the serum was also measured with commercially available assay kits (IMMULITE 2000 Intact PTH, Diagnostic Products Corporation, Los Angeles, CA, USA).
The data obtained were evaluated by analysis of variance (ANOVA). Post hoc tests were performed with Bonferroni's test. Statistical significance was considered as a P < 0.05.
Mean Percent of Porosity
Osteoporosis is diagnosed by its relatively very low bone mineral density (BMD). Moreover, many women who are osteopenic eventually develop osteoporotic fractures . The adult ovariectomized rat is a convenient and reliable experimental model for the evaluation of agents intended to prevent and/or treat postmenopausal osteoporosis. Like humans, rats have cancellous bone that undergoes remodeling once longitudinal growth has essentially ceased . In adult rats, ovariectomy is followed by an increase in bone turnover associated with bone loss and a permanent deficit of bone mass at several skeletal sites, including the vertebral bodies, the proximal femur, and the metaphyses of long bones, such as the distal femur and proximal tibia . In the current study, the decrease in bone mass after ovariectomy was observed in the femur, tibia, and spine, but it was more evident in the metaphysis of the long bones (Figures 2 and 4).
After treatment with an isoflavone-rich diet for three months, most of the biochemical parameters in serum did not show any significant changes. Only the serum titers of CRE, GPT, and PTH were higher than that of the preoperative baseline values, but there were no statistically significant differences between the groups at the end of the study (Figure 1). This observation can be partially explained by the younger group of premenopausal rats with higher endogenous estrogen and active physiologic bone formation at this age  or possibly there was no obvious detrimental physiological effect of an isoflavone-rich diet on this particular animal model.
When compared with the sham-operated rats fed a normal diet (Group A), the bone mass of rats with a normal diet after ovariectomy (Group B) decreased significantly. Pre-ovariectomy ingestion of an isoflavone-rich diet for one month did not prevent rats from bone loss (Group C). As noted in this study, the bone ashes analysis revealed a greater than 40% reduction in whole tibial bone mass, greater than a 30% reduction in whole spine bone mass, and greater than a 10% reduction in whole femur bone mass two months following ovariectomy (Figure 2). Following ovariectomy, the microarchitectural alterations in cancellous bone were similar to those observed in postmenopausal and age-dependent osteoporosis, which produced architectural discontinuities of cancellous bone (Figure 3). The lack of an effect of pretreatment with an isoflavone-rich diet in ovariectomized rats is striking, in contrast to its effects on the bone of the ovariectomized animals fed an isoflavone-rich diet for three months. An explanation of this lack of effect is not apparent. Reduction of bone mass in the ovariectomized rats pretreated with an isoflavone rich-diet suggests that premenopausal isoflavone supplementation cannot prevent bone loss and osteoporosis following the menopause. Further, in this rat ovariectomy model, the different degree of bone loss reflects the fact that the early postovariectomy period is characterized primarily by loss of bone mass in the long bones such as the tibia and femur, rather than in the spine.
In this study, the rats were young adults and had not yet achieved the slowest phase of growth. We found that although prolonged isoflavone-rich diet intake has a positive effect on the bone mass, the cessation of an isoflavone-rich diet intake does not guarantee that the bone-sparing effect will persist. This raises the question whether the presence of a well-formed and active growth plate may have affected the action of an isoflavone-rich diet on bone. This fact can be partially explained by the use of growing animals, as the remodeling of the primary spongiosa is also suppressed and the increase in bone area is not only due to a stimulation of growth but also may be due to the failure to remodel the primary spongiosa. Studies in older rats, or ideally in another experimental model that has a true Haversian system and with remodeling cancellous bone, would help to answer this question.
The bone mass of the rats with ingestion of an isoflavone-rich soy protein isolate for three months still higher than that of the sham-operated normal control even at two months after ovariectomy. The treatment of rats with an isoflavone-rich diet for three months resulted in an approximately 40–60 % increase of bone mass in the long bones even when measured two months after ovariectomy (Figure 2). These findings are consistent with the recent report of Arjmandi BH et al. (1996) that dietary intake of soybean products prevents bone loss after ovariectomy . In a human study, Mei et al. demonstrated that a habitually high intake of dietary isoflavone is associated with a higher bone mineral density value in both the spine and hip regions, while no association existed between dietary phytoestrogen intake and bone mineral density value in premenopausal women with high endogenous estrogen . In this study, because there were no bone ash and histology or histomorphometry measurement on animals after one month feeding isoflavones, we can not concluded that habitual ingestion of an insoflavone-rich diet during the premenopause had a protective effect against bone loss after ovariectomy. The bone-sparing action did observed in the treated group with long-term ingestion of an isoflavone-rich diet. The bone-sparing action of isoflavone supplementation primarily effect the metaphyseal portion of the proximal tibia and the vertebrae of spine. Customarily, high isoflavone intake may also help to reverse the state of secondary hyperparathyroidism associated with estrogen withdrawal and hence lower the rate of bone turnover in postmenopausal women . In our study, the rats fed with an isoflavone-rich diet were protected completely from bone loss after castration, which is similar to that reported by Arjmandi et al. . Whether the discrepancy between our study and that of Arjmandi et al.  is that bone mass was increased after intake of an isoflavone-rich diet for three months need to be further validated in the future study.
The possibility that the effect of 25 mg/rat/day of isoflavones on bony tissues of the ovariectopmized rats is via a non-estrogenic mechanism is supported by the presented noninvasive and histological results. In fact, the higher number of bone tracbeculae measured in the ovariectomized- rats fed an isoflavone-rich soy protein isolate is indicative of a preventive effect of isoflavones on bone loss (Figure 3). This response of bone is different from that expected following administration of estradiol, since most investigators have reported that the rate of bone formation of ovariectopmized rats is suppressed, rather than stimulated, by exogenous estradiol [27–29]. Whether the preventive effect on bone loss of an isoflavone-rich diet on bone formation is mediated by a preferential interaction of this ligand with the estrogen receptor β, or by interaction with selective estrogen receptor modulators such as the raloxifene-response element, or by non-receptor-mediated direct effects on specific intracellular enzymes, warrants future investigation.
In summary, there are limitations in this study. The first one is the animal age, which is much younger than that usually used for the postmenopusal model; the second one is that the bone histological study used in this study is mainly a 2-dimensional approach with inherent model-based assumption, i.e., indirect measurement of microstructure; and the housing of rats individually may be also a stressor that confounds interpretation . However, the premenopausal ingestion of isoflavone does not prevent the development of post-ovariectomized bone loss, while the habitual ingestion of an isoflavone-rich diet does increase the bone mineral contents in the long bones of ovariectomized rats. The mechanism by which an isoflavone-rich soy protein isolate acts on bone resorption is still unknown and should be the subject of additional investigation.
The authors thank the financial support from the National Science Council, R.O.C. and the technical support from King Car Food Industrial Co., Ltd (Taipei, Taiwan, ROC).
- Greendale GA, Barrett-Connor E, Ingles S, Haile R: Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo study. J Am Geriatr Soc. 1995, 43: 955-61.View ArticlePubMedGoogle Scholar
- National Osteoporosis Foundation: Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int. 1998, 8 (suppl 4): S1-S88.View ArticleGoogle Scholar
- Ray NF, Chan JK, Thamer M, Melton LJ: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997, 12: 24-35. 10.1359/jbmr.19188.8.131.52.View ArticlePubMedGoogle Scholar
- Johnell O: The socioeconomic burden of fractures: today and in the 21st century. Am J Med. 1997, 1032A: S20-6. 10.1016/S0002-9343(97)90023-1.View ArticleGoogle Scholar
- Maggi S, Kelsey JL, Litvak J, Heyse SP: Incidence of hip fractures in the elderly: a cross-national analysis. Osteoporos Int. 1991, 1: 232-41.View ArticlePubMedGoogle Scholar
- Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ: Vertebral fracture prevalence in women in Hiroshima compared to Caucasian or Japanese in the US. Inc J Epidemiol. 1995, 24: 1171-7. 10.1093/ije/24.6.1171.View ArticleGoogle Scholar
- Lau EMC, Cooper C: The epidemiology of osteoporosis: the oriental perspective in a world context. Clin Orthop. 1996, 323: 65-74. 10.1097/00003086-199602000-00009.View ArticlePubMedGoogle Scholar
- Levi G, Geoffroy V, Palmisano G, de Vernejoul MC: Bones, genes and fractures: Workshop on the genetics of osteoporosis: from basic to clinical research. EMBO Rep. 2002, 3: 22-6. 10.1093/embo-reports/kvf003.PubMed CentralView ArticlePubMedGoogle Scholar
- Holbrook TL, Barrett-Connor E, Wingard DL: Dietary calcium and risk of hip fracture: 14 year prospective population study. Lancet. 1988, 2: 1046-9. 10.1016/S0140-6736(88)90065-7.View ArticlePubMedGoogle Scholar
- Hegsted DM: Calcium and osteoporosis. J Nutr. 1986, 116: 2316-9.PubMedGoogle Scholar
- Abelow BJ, Holford TR, Insogna KL: Cross-cultural association between dietary animal protein and hip fracture: a hypothesis. Calcif Tiss Int. 1992, 50: 14-8. 10.1007/BF00297291.View ArticleGoogle Scholar
- Arena S, Rappa C, Del Frate E, Cenci S, Villani C: A natural alternative to menopausal hormone replacement therapy. Phytoestrogens. Minerva Ginecol. 2002, 54: 53-7.PubMedGoogle Scholar
- Adlercreutz H: Western diet and western disease: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990, 50 (Suppl 201): S3-23. 10.3109/00365519009085798.View ArticleGoogle Scholar
- Miksicek RJ: Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol. 1994, 49: 153-60. 10.1016/0960-0760(94)90005-1.View ArticlePubMedGoogle Scholar
- Messina M: Modem applications of an ancient bean: soybeans and the prevention and treatment of chronic disease. J Nutr. 1995, 125: S567-9.Google Scholar
- Sirtori CR, Lovati MR, Manzoni C, Monetti M, Pazzucconi F, Gatti E: Soy and cholesterol reduction: clinical experience. J Nutr. 1995, 125 ((3 suppl)): 598S-605S.PubMedGoogle Scholar
- Adlercreutz H, Hämäläinen E, Gorbach S, Goldin B: Dietary phytoestrogens and the menopause in Japan. Lancet. 1992, 339: 1233-10.1016/0140-6736(92)91174-7.View ArticlePubMedGoogle Scholar
- Agnusdei D, Gennari C, Bufalino L: Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone active drug ipriflavone. Osteoporos Int. 1995, 5: 462-6. 10.1007/BF01626609.View ArticlePubMedGoogle Scholar
- Notoya K, Yoshida K, Tsukuda R, Taketomi S, Tsuda M: Increase in femoral bone mass by ipriflavone alone and in combination with 1α-hydroxyvitamin D3 in growing rats with skeletal unloading. Calcif Tissue Int. 1996, 58: 88-94.View ArticlePubMedGoogle Scholar
- Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW: Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998, 68 ((6 Suppl)): 1375S-1379S.PubMedGoogle Scholar
- Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T: Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000, 72: 844-52.PubMedGoogle Scholar
- Lieber CS, DeCarli LM: The feeding of alcohol in liquid diets: two decades of applications and 1982 update. Alcohol Clin Exp Res. 1982, 6: 523-31. 10.1111/j.1530-0277.1982.tb05017.x.View ArticlePubMedGoogle Scholar
- Rosen CJ, Beamer WG, Donahue LR: Defining the genetics of osteoporosis: using the mouse to understand man. Osteoporos Int. 2001, 12: 803-10. 10.1007/s001980170030.View ArticlePubMedGoogle Scholar
- WHO Technical report Series, No. 843: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. 1994, Geneva, World Health Organization, [WHO Technical Report Series, No. 843].Google Scholar
- Mei J, Yeung SS, Kung AW: High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab. 2001, 86: 5217-21. 10.1210/jc.86.11.5217.View ArticlePubMedGoogle Scholar
- Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewicz-Sapuntzakis M, Guo P, Kukreja SC: Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr. 1996, 126: 161-7.PubMedGoogle Scholar
- Westerlind KC, Wakley GK, Evans GL, Turner RT: Estrogen does not increase bone formation in growing rats. Endocrinology. 1993, 133: 2924-34. 10.1210/en.133.6.2924.PubMedGoogle Scholar
- Kalu DN, Liu CC, Salerno E, Hollis B, Echon R, Ray M: Skeletal response of ovariectomized rats to low and high doses of 17pestradiol. Bone Miner. 1991, 14: 175-87. 10.1016/0169-6009(91)90021-Q.View ArticlePubMedGoogle Scholar
- Wronski TJ, Cintrón M, Doherty AL, Dann LM: Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Eridocrinology. 1988, 123 (2): 681-686.View ArticleGoogle Scholar
- Wronski TJ, Li M, Shen Y, Miller SC, Bowman BM, Kostenuik P, Halloran BP: Lack of effect of spaceflight on bone mass and bone formation in group-housed rats. J Appl Physiol. 1998, 85 (1): 279-285.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.